Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Strategy

Set Alert for Strategy

Slovenia Is Our Commitment; Evotec Is A Gamechanger: Sandoz’s Stenico

On the sidelines of Medicines for Europe’s 19th biosimilar conference in Amsterdam, Sandoz global biosimilars chief Peter Stenico spoke to Generics Bulletin about the firm’s preparations and strategy ahead of its proposed spinoff from Novartis later this year.

Biosimilars Strategy

MGC And GlycoNex Kick Off Denosumab Trial In Japan

Mitsubishi Gas Chemical Company and GlycoNex have begun a Phase I trial in Japan for their SPD8 denosumab biosimilar. The partners are also “actively pursuing global development plans” for the rival to Prolia and Xgeva.

Biosimilars Clinical Trials

Neuraxpharm Brings In Greek Olanzapine Brand

CNS specialist Neuraxpharm has snapped up the Lazap olanzapine brand in Greece from local firm Lyofin, helping to further expand its presence in the Greek market following a recent acquisition.

Deals Greece

Dr Reddy’s Takes Another Step Forward On Tocilizumab

Dr Reddy’s has notched up another achievement for its biosimilar tocilizumab candidate, after the intravenous presentation of the firm’s proposed Actemra/RoActemra rival completed a Phase I study.

Biosimilars Clinical Trials

Zydus Looks To NASH Trials In Turkey, Generic Vascepa Launch In The US

Zydus, the only Indian company with an NCE for a range of chronic liver diseases, will add Turkey to the list of trial locations for NASH. It is also working “aggressively” to launch a generic to Amarin’s Vascepa after Revlimid and Trokendi generics drove record US sales in the fourth quarter.

Strategy Generic Drugs

Generics Bulletin Explains: Sandoz’s Spinoff From Novartis

Ahead of a Sandoz capital markets day on 8 June, Generics Bulletin explains what we know so far about the firm’s spinoff from parent company Novartis – as well as the questions that the companies are yet to answer.

Strategy Deals

Indoco Builds On Recent Growth With Acquisition In US

Indoco says it has marked a major milestone with a $4m deal to take a controlling stake in US firm Florida Pharmaceutical Products, strengthening the Indian company’s position in the US market.

Deals M & A

Dr Reddy’s CEO: We’re In ‘Great Dialogue’ With The Innovation Industry In China

Dr Reddy’s is collaborating with innovator firms in China, Israel and the US largely in areas of unmet need, propelling its “Horizon-2” strategy that encompasses segments like biologics and cell and gene therapy, digital services and immuno-oncology NCEs, among others.

Strategy Deals

Sandoz Reveals New Headquarters Post Spin, Mid-2024 Date Outlined

Tracing its roots back to Basel in the late nineteenth century, Sandoz has confirmed the location of its new planned permanent headquarters post-spin.

Strategy Companies
See All
UsernamePublicRestriction

Register